West Pharmaceutical Services, Inc. (WST)
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.85 per share a year ago.
WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?
West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.
West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2025 Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Bank of America Global Healthcare Conference 2025 September 24, 2025 10:05 AM EDT Company Participants Eric Green - Non-Independent Chair of the Board, President & CEO Robert McMahon - Senior VP & CFO Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division Thanks for joining us for our next session. My name is Mike Ryskin.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
Wall Street Analysts See a 28.68% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High?
The mean of analysts' price targets for West Pharmaceutical (WST) points to a 28.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think West Pharmaceutical (WST) Could Surge 25.26%: Read This Before Placing a Bet
The consensus price target hints at a 25.3% upside potential for West Pharmaceutical (WST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
West Pharmaceutical (WST) Upgraded to Strong Buy: Here's Why
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
West Pharmaceutical Services: Low Debt, High Profit, And A Waning Destocking Problem
My estimations suggest that the U.S. government cuts to its healthcare system will not have a significant negative impact on West Pharmaceutical's revenues. In Q2 2025, the company's revenues increased by 9.17%, suggesting that the destocking effect is vanishing. The company has low debt levels, achieving a liabilities-to-assets ratio of 25.90% in Q2 2025. Additionally, it achieved a 17.03% net profit margin in 2024.
West Pharmaceutical Services, Inc. (WST) Q2 2025 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Bernard J. Birkett - Senior VP & CFO Eric M.
WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit
West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
West Pharmaceutical Services (WST) Surpasses Q2 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.52 per share a year ago.
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.
